Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Licenses Probe Technology to Quest

NEW YORK (GenomeWeb News) – Nanogen has licensed its minor groove binder probe technology to Quest Diagnostics for use in human in vitro diagnostics tests.

Clinical lab firm Quest will pay Nanogen an undisclosed upfront fee and royalties based on sales of products that incorporate the MGB Probe technology.

Nanogen noted that licensing deals for the MGB Probe technology now represents the majority of Nanogen's revenues. It said that it has more than 40 reagent and kit products sold for IVD use usnder the MGB Alert and Q-PCR Alert brands.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.